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ABSTRACT 
Secretin, the first hormone discovered by Bayliss and Starling in 1902, is 
mainly synthesized and released from the endocrine S cells located in the mucosa of 
the upper small intestine in numerous mammalian species. Its primary function is to 
stimulate bicarbonate, electrolyte and volume secretion from pancreatic ductule 
epithelial cells, and its potential as a neuropeptide has not been recognized yet. The 
recent discovery of the therapeutic potential of secretin in treating autistic patients, 
together with the conflicting reports on its effectiveness, urges an in-depth 
investigation of this issue. 
Whole-cell patch clamp recordings were carried out in the rat cerebellar slices 
to explore the function of secretin in the central nervous system (CNS). It was 
demonstrated that in the rat cerebellar cortex, secretin facilitates evoked, spontaneous 
and miniature GABAA-mediated inhibitory postsynaptic currents (IPSCs) recorded 
from Purkinje cells in a dose-dependent manner. Secretin acted at a presynaptic site 
because the frequency of the miniature IPSCs was facilitated. This facilitation on 
miniature IPSCs was inhibited by an adenylate-cyclase inhibitor SQ22536 and was 
mimicked by forskolin and 3-isobuty 1-1 -methyIxanthine (IBMX) that increase the 
intracellular c A M P level, suggesting the involvement of G-protein coupled adenylyl 
c A M P second messenger system. Furthermore, this effect of secretin was insensitive 
to Cd2+, a Ca2+ channel blocker indicating the independence on -influx pathway. 
O n the other hand, the function of secretin was associated, at least partly, with an 
action of presynaptic A M P A receptors, which was proved for the first time to 
facilitate constitutive G A B A release onto rat cerebellar Purkinje cells. This hypothesis 
was supported by the finding that an A M P A receptor antagonist, 6-cyano-7-
ii 
nitroquinoxaline-2,3-dione (CNQX), weakens the facilitation of secretin on miniature 
IPSCs. 
According to these electrophysiological data, secretin does facilitate G A B A 
transmission in the rat cerebellum, and therefore acts as a neuropeptide. Combined 
with the previously reported data on in situ hybridization and immunohistochemistry, 
we propose that secretin is released from the somatodentritic region of Purkinje cells 
and serves as a retrograde messenger, modulating the GABAergic afferent plasticity 
and hence their own excitability. These novel results on the role of secretin in C N S 
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A C S F Artificial cerebral spinal fluid 
A M P A Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 




C N Q X 6-cyano-7-nitroquinoxaline-2,3-dione 
C N S Central nervous system 
Die Differential interference contrast 
EC50 50 % Effective concentration 
G-protein Guanine nucleotide binding proteins 
G A B A y-Aminobutyric acid 
G T P Guanylyl triphosphate 
I B M X 3 -isobutyl-1 -methylxanthine 
IPSC Inhibitory postsynaptic current 
I E P S C Excitatory postsynaptic current 
i K-S test Kolmogorov-Smirnov test 
i 
丨 P C Purkinje cell 
P K A Protein kinase A 
P K C Protein kinase C 
ti/2 50 0/0 Decay time 






1.1 Overview of the study 
Secretin possesses a truly unique position in the history of endocrinology. It was the 
first hormone discovered by Bayliss and Starling in 1902 (Bayliss and Starling, 1902) 
that launched the whole concept of endocrine regulation. Today, the essential roles of 
secretin as a hormone in the pancreas and gastrointestinal tract are firmly established. 
On the contrary, there is still no convincing evidence to indicate the neuroendocrine 
function of secretin in the central nervous system, although there is some evidence 
accumulated in the past 20 years to suggest that secretin is present in the brain and is 
neuroactive. However, up to the present, neither has Northern blot analysis detected 
secretin receptor transcripts in any part of the human brain tested, namely amygdala, 
caudate nucleus, corpus callosum, hippocampus, substantia nigra, subthalamic 
nucleus, and thalamus (Chow, 1995), nor has there been any direct 
electrophysiological evidence to indicate that secretin can modulate the excitability or 
I 
function of central neurons. 
I 
\ Recently, the question of whether secretin is neuroactive received a renewed 
•j 
\ attention. The reported improvement in the behaviors of autistic children receiving 
secretin injections supports this idea (Horvath et al., 1998). However, there are other 
i conflicting reports on the effectiveness of secretin in treating autism (Sandler et al, 
1999; Chez et al., 2000)。There is also evidence to suggest a correlation between 
autism and abnormalities in the cerebellum (Courchesne, 1997; Riva and Giorgi, 
1 
2000). These findings thus urge an in-depth investigation on the neuroendocrine roles 
of secretin, particularly the relevant neuronal pathways and mechanisms involved in 
exerting its actions. In the present study, we aim to answer these questions by 
examining the in vitro electrophysiological effects of secretin on central neurons. 
Using the patch-clamp technique, we found that secretin facilitates G A B A 
transmission in the rat cerebellum as a neuropeptide. Interestingly, presynaptic A M P A 
receptors, a type of ionotropic glutamate receptors (iGluRs), play a fundamental role 
in the mechanism of the actions of secretin in the cerebellum. 
In the following sections, a literature review summarizing our current 
knowledge of secretin, secretin receptor, A M P A receptor and cerebellum is given. In 
Chapter 2, the techniques used in the current study are described. In Chapter 3, the 
basic pharmacological and kinetic properties of GABA-mediated IPSCs in Purkinje 
cells are described followed by the results on the effects of secretin and A M P A , 
together with the exploration on their mechanisms. The functional roles played by 
secretin, A M P A and their receptors, including the physiological significance of them 
in the cerebellum, are discussed in Chapter 4. 
2 
1.2 Secretin 
Secretin is a member of a family of peptides, the vasoactive intestinal polypeptide 
(VlP)-secretin-glucagon family, which also includes pituitary adenylate cyclase-
activating polypeptide (PACAP), gastric inhibitory polypeptide (GIP), parathyroid 
hormone (PTH), growth hormone-releasing hormone (GHRH), and exendins 
(Nussdorfer et al., 2000; Chow et al., 1997; Paul and Ebadi, 1993). All the members 
of this peptide family possess a remarkable amino-acid sequence homology, are 
widely distributed in the body, and exert pleiotropic physiological effects, in many 
instances acting in a paracrine manner. 
1.2.1 Discovery 
Secretin was first discovered as a gastrointestinal hormone by Bayliss and Starling in 
1902. They showed that an injection of the upper intestinal mucosal extract into an 
anesthetized dog resulted in the stimulation of pancreatic secretion and hepatic bile 
flow (Bayliss and Starling, 1902). The chemical messenger secreted by the intestinal 
mucosa in the extract that exerted these physiological effects was named as secretin 7 
days after its discovery. 
Since then, people began to acquire the concept of endocrine regulation and 
endocrinology had been launched as a new branch of science (Welbourn, 1992). In 
1905, the word “hormone，，coming from Greek was proposed by Starling to represent 
the class of internal secretion that passes into the blood and stimulates the bodily 
organs. Secretin has the honor to be the first hormone recognized by people. 
3 
1.2.2 Molecular biology 
Secretin is a 27-amino acid residue C-terminally amidated peptide with a molecular 
weight of 3055 (Mutt et aL, 1970). The amino acid sequence is His-Ser-Asp-Gly-Thr-
Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-
Gln-Gly-Leu-Val-NHi. It had been purified and sequenced from porcine (Mutt et aL, 
1970), chicken (Nilsson et al, 1980), bovine (Carlquist et al., 1981), dog (Shinomura 
et al, 1987) and rat (Gossen et al., 1989). In these species secretin was highly 
conserved except in the chicken. 
The organization of the secretin gene is similar to that of the genes of the other 
members of VIP-secretin-glucagon family. The coding region of the secretin gene of 
rat and mouse contains four exons separated by three short introns (Itoh et al., 1991; 
Lan et aL, 1994). The structure of porcine, rat and mouse preprosecretin contains a 
signal sequence, a N-terminal flanking peptide, secretin and a C-terminal extension 
peptide. Rat preprosecretin contains 134-amino acids, whereas that of pigs is shorter, 
due to the lack of some residues at the N-terminus of the signal peptide. Mouse 
preprosecretin contains 133 amino acids and exhibits 88% and 80% homology with 
those of rats and pigs (Bonetto et al,, 1995; Calquist et al., 1981, Gafvelin et al., 1990, 
Itoh et al., 1991, Kopin et al., 1990; Lan et al., 1994). 
1.2.3 Biosynthesis and localization 
Secretin is synthesized and released from the endocrine epithelial S cells located in 
the mucosa of the upper small intestine in numerous mammalian species (Straus and 
Yalow, 1978; Inokuchi et al,, 1985). The S cells that produce secretin had been 
characterized by immunofluorescence (Polak et al., 1971; Bussolati et al” 1971). 
4 
As a traditional endocrine peptide, secretin is distributed primarily in the 
gastrointestinal tract (Daniel, 1990). Immunoreactive secretin in hydrochloric acid 
extracts is relatively constant in the duodenum and proximal jejunum of pig and dog, 
but peaks in the distal duodenum of guinea pig, with no secretin being detectable in 
the ileum of these species. Relatively constant amount of secretin is present 
throughout the small intestine of the rat and rabbit (Straus and Yalow, 1978). 
However, no secretin immunoreactivity was detected in the large intestine except the 
porcine colon (Yanaihara et al,, 1977). Except intestine, secretin immunoreactivity 
was also detected in gastric antrum (Chey et al., 1983) and pancreatic monolayer and 
islet (Rufener et al., 1976; Wheeler et al., 1992), other organs including heart, liver, 
lung, kidney, ovary, testis and even the brain (Ohta et al,, 1992). 
Worthy of special attention, in the past 20 years more and more evidence 
suggests that secretin is distributed and bio active in the central nervous system, 
especially in the brain. For example, secretin-like bioactivity and immunoreactivity 
were found in mammalian brain extracts (O'Donohue et al, 1979; Mutt et al, 1979). 
In rat and pig brains, the secretin immunoreactivity in regions of pituitary, pineal 
gland, hypothalamus, thalamus and olfactory lobe is comparable to that in small 
intestine (O'Donohue et al, 1981). High-affinity binding sites to rat brain membranes 
for secretin had also been detected (Fremeau et al, 1983). With RT-PCR technique, 
secretin m R N A transcripts have been detected to be widely distributed in various 
regions of the rat brain, such as cortex, hypothalamus, medulla oblongata, pons, 
pituitary, brainstem and hypophysis (Charlton et al., 1982; Fremeau et al, 1983; 
Kopin et al, 1990; Kopin et al, 1991; Itoh et al, 1991; Mckeon and Zigmond, 1993; 
Roskoski et al, 1989). These suggest that secretin may also function as a 
neurotransmitter or neuromodulator. 
5 
1.2.4 Function 
As a traditional hormone, the primary action of secretin in stimulating bicarbonate, 
electrolyte volume and enzyme secretion from pancreatic ductule epithelial cells is 
firmly established (Bayliss and Starling, 1902; Daniel, 1990; Rausch et al., 1985). 
Other physiological actions of secretin in the digestive system include inhibition of 
gastrin secretion (You and Chey, 1987), inhibition of gastric emptying and acid output 
(Raybould and Holzer, 1993; Jin et al., 1994; Valenzuela and Defilippi, 1981; 
Kleibeuker et al,, 1984), stimulation of hepatic bile flow (McGill et al., 1994), 
functioning as a mitogen to promote pancreatic growth (Solomon et al., 1978; 
Petersen et al., 1978), stimulation of mucus, as well as bicarbonate and epidermal 
growth factor secretion from duo denal Brunner's glands (Olsen et al., 1994). Apart 
from the digestive system, secretin also affects cardiac and renal function (Gunnes et 
al., 1989; Charlton et al., 1986). The mechanism on the actions of secretin is 
complicated and not well documented. Some evidence shows that secretin exerts 
electrophysiological effects on ion channels through a cAMP-dependent mechanism 
and hence induces the change in the cell activity. For example, it has been reported 
that secretin activates CI" channels in bile duct epithelial cells and pancreatic duct 
cells (McGill et al., 1994; Gray et al., 1988), and augment cardiac L-type calcium 
channel currents in isolated adult rat ventricular myocytes (Tiaho and Nerbonne, 
1996). 
Secretin is also biologically active in mammalian central and peripheral 
nervous systems. Intracerebroventricular injection of secretin in rats produces 
metabolic, physiologic, and behavioral alterations including stimulation of 
hypothalamic tyrosine hydroxylase activity (Babu and Vijayan, 1983) and 3,4-dihy-
6 
droxyphenylethylamine (dopamine) metabolism (Fuxe et al, 1979), a reduction in 
prolactin and luteinizing hormone secretion (Babu and Vijayan, 1983; Fuxe et al, 
1979; Samson et al., 1984), alterations in respiration, and reductions in open field 
activity and novel item approach (Charlton et al., 1983). In the rat superior cervical 
ganglion and PC-12 pheochromocytoma cells, secretin acutely stimulates tyrosine 
hydroxylase activity and elevates ganglionic cyclic A M P levels (Ip et al., 1982; Ip et 
al., 1985; Roskoski et al, 1989). These data together with the evidence on 
endogenous secretin-like bioactivity and immunoreactivity in mammalian brains (see 
last section) suggest that secretin may function as neuroregulatory agents in 
mammalian central and peripheral nervous systems. However, little is known about 
the mechanism by which secretin alters neuronal activity, except that secretin 
increases c A M P concentration in a variety of brain areas (Fremeau et al, 1986; Van 
Calker et al, 1980). 
7 
1.3 Secretin receptor 
The functions of secretin are mediated via its specific interactions with cell surface 
receptors. The secretin receptor belongs to the glucagon-VIP-secretin receptor family 
that is recently described as the distinctive class II family of G protein-coupled 
receptors (GPCRs). Also included in the secretin receptor family are receptors for 
P A C A P (Spengler et al, 1993), GIP (Usdin et al, 1993), glucagons (Jelinek et al, 
1993), glucagon-like peptide 1 (Thorens, 1992), calcitonin (Lin et al, 1991), 
calcitonin gene-related peptide (Aiyar et al, 1996), parathyroid hormone (Juppner et 
al, 1991), growth hormone-releasing factor (GHRF) (Godfrey et al, 1993), 
corticotropin-releasing factor (Chang et al, 1993), insect diuretic hormone (Reagan et 
al, 1994), and a few orphan receptors or more distantly related molecules. These 
receptors share substantial homology with each other, and all bind moderate-sized 
peptides possessing diffuse pharmacophoric domains (Ulrich et al, 1998). 
1.3.1 Molecular biology 
A complementary D N A corresponding to the rat secretin receptor (RSR) isolated 
from the NG108-15 cell-line was first cloned in 1991 among the members of the 
secretin receptor family (Ishihara et al, 1991). The human secretin receptor (HSR) 
cDNAs have also recently been cloned, characterized and functionally expressed from 
the human pancreatic adenocarcinoma cell-line and human lung tissues (Chow, 1995; 
Jiang and Ulrich, 1995; Patel et al, 1995). 
The nucleotide sequence analysis of the R S R c D N A has revealed that the R S R 
consists of 449 amino acids with a calculated molecular (Mr) weight of 48,696 
(Ishihara et al, 1991). While the H S R is a 440-amino acid polypeptide with a 
predicted M r of 50 kD encoded by a 1616,1717 or 1.8k-base pair c D N A (Patel et al, 
8 




I homology in amino acids with the R S R and 37% with the human type 1 VIP receptor 
(Patel et al, 1995). 
The H S R gene consists of 13 exons and 12 introns with all the splice donor 
i 
I -i 
I and acceptor sites conforming to the canonical G T / A G rule (Ho et al, 1999). Similar 
i. 
I to other members in the secretin receptor family, the secretin receptor has a relatively 
long extracellular hydrophilic amino-terminal domain (144 amino acids) containing 
six highly conserved Cys residues and one Cys residue (Cys(ll)) that is present only 
i j 
[ in the most closely related family members (Asmann et al, 2000), seven highly 
conserved hydrophobic transmembrane-spanning helical domains including 3 
i 
intracellular and 3 extracellular loops (254 amino acids) (Tarns et al, 1998), and a 
i -
hydrophilic cytoplasmic tail (42 amino acids). The amino acids homology between 
H S R and R S R is greatest within the transmembrane domains; however, H S R differs 
from R S R in having four additional residues in the amino-terminal region and nine 
I fewer residues in the carboxyl-terminal tail segment (Patel et al, 1995). The 
importance of the N-terminal ectodomain in ligand binding and interaction was 
I indicated by domain swapping experiments (Holtmann et al, 1995; Holtmann et al, 
1996), and by a novel approach using the recombinant ectodomain to functionally 
I antagonize the wild-type receptor (Chow, 1997). The carboxyl-terminal tail of the 
I secretin receptor plays an important role in the agonist-stimulated phosphorylation 
(Ozcelebi et al, 1995). 
1.3.2 Localization 
！ 
The secretin receptor is primarily expressed in pancreas. In rat pancreas, in situ 




demonstrated that the secretin receptor is highly expressed on both acinar and duct 
cells with a uniform lobular distribution, but apparently absent or extremely low in 
i 
I density on islets and pancreatic vascular structures (Ulrich et al, 1998). Other organs 
\ containing the secretin receptor expression in rat include heart and stomach (Ishihara 
et al, 1991). Northern blot analysis of various human tissues indicated that the 
secretin receptor is expressed in the pancreas, small intestine, kidney, colon and lung 
(Chow, 1995; Patel et al, 1995). Northern blot analysis of human tissue m R N A 
revealed that the relative intensity for expression of a 2.1 -kilobase H S R transcript was 
pancreas > kidney > small intestine > lung > liver, with trace levels in brain, heart, 
and ovary (Patel et al, 1995). 
However, the results on Northern blot analysis of the secretin receptor 
transcripts in the brain are not consistent in the past. It has been demonstrated that 
various rat brain regions have high-affinity binding sites for secretin (Fremeau et al, 
1983). Northern blot analysis performed by Patel et al (1995) also supports the 
presence of secretin receptor m R N A in the human brain. On the contrary, the similar 
experiments done by Chow (1995) suggested no secretin receptor transcript signal in 
the human brain, including amygdala, caudate nucleus, corpus callosum, 
hippocampus, substantia nigra, sub-thalamic nucleus and thalamus; nor did the study 
of Ishihara et al (1991) in the rat brain tissues. These contradictory data suggested the 
shortage of the Northern blot analysis technique at the current stage, and urged the 
further exploration on the secretin receptor in the brain. 
Inspiringly, the latest investigation using reverse transcription-polymerase 
chain reaction (RT-PCR) by our collaborators, Dr. B.K.C. Chow et al (Yung et al., 
I 
j 2001), revealed a conspicuous expression of both secretin and secretin receptor in the 




I . . 
I Northern blot analysis using partial c D N A probes corresponding to rat secretin 
I '1 
(nucleotides 1-453) (Ishihara et al., 1991) and secretin receptor (nucleotides 213-639) 
(Kopin et al., 1990). Positive hybridization signals for both the ligand and the receptor 
were detected in the rat cerebellum (Fig. 1.1 A). To determine the cellular distributions 
I 
I of the transcripts, in situ hybridization was carried out by our collaborators, Dr. P.S. 
I 
Leung (Yung et al., 2001). It was found that Purkinje cells strongly expressed secretin I 
I 
I m R N A , which was absent in the molecular and the granule cell layers (Fig. LIB). On 
i the other hand, secretin receptor m R N A was expressed in both the molecular layer 
. 1 
I and the Purkinje cell layer (Fig. I.IC). Within the molecular layer, hybridization 
i •i 
j signals were found in the soma of basket cells located in the vicinity of Purkinje cells. 
Immunohistochemistry was then carried out to determine the expression of the 
I secretin peptide in the rat cerebellum. In agreement with the in situ hybridization 
result, within the cerebellar cortex, secretin-immunoreactivity was found only in 
i 
i Purkinje cells. Both the soma and the dendrites of these cells were positively 
immunostained (Fig. I.ID). 
i 
丨 1.3.3 Signal transduction pathway 
I Since all the members of the secretin receptor family are able to couple to Gs protein 
i leading to the production of intracellular cAMP, the secretin receptor is a G-protein-
i coupled receptor that is functionally linked to the c A M P second messenger system by 
I Stimulation of adenylate cyclase. Distinct receptors for secretin that are coupled to the 
elevation of intracellular c A M P through a Gs protein have been characterized in 
； guinea pig pancreatic acini (Haffar et al, 1991; Jensen et al, 1983), rat gastric glands 
(Bawab et al, 1988), rat liver cholangiocytes (Kato et al, 1992), mouse N18TG2 
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Figure 1.1 Expression of secretin and secretin receptor in the rat cerebellum. A, In 
Northern blot analysis, positive signals for secretin and its receptors were detected. B, 
In in situ hybridization, intense signals for secretin m R N A were detected using 
antisense (left) but not sense probes, and were clearly confined to the Purkinje cell 
layer (right). C, strong signals for the secretin receptor m R N A were detected in both 
the Purkinje cell layer and the molecular layer using the antisense (left) but not the 
sense probe (right). Higher magnification (not shown) reveals that the signals were 
found in both the Purkinje cells and nearby basket cells. Basket cells were identified 
by their location in the deep internal zone and their large-nucleus soma; scale bar = 
200 |Lim. D，Immunoreactivity for secretin was confined to the soma and dendrites of 
Purkinje cells (left), and was absent in consecutive control sections (right) incubated 
i 
with antiserum preabsorbed with secretin; scale bar = 40 |am. GL, granule cell layer; 




hybrid cells (Gossen et al, 1990), cultured brain cells (Van Calker et al, 1980), and 
rat frontal cortex (Fremeau et al, 1986). 
Besides the cAMP, other intracellular second messengers such as 
Ca2+ and 
j 
I inositol-l,4,5-trisphosphate have also been reported to play a role in the signal 
transduction of secretin receptor. For example, activation of secretin receptors 
•i 
j resulted in an increase in the intracellular calcium level in 293S12 cells and a 4-fold 
j 
j increase in phosphatidylinositol hydrolysis (Patel et al, 1995). In rat pancreatic acini, 
J 
j the stimulation of secretin on amylase secretion was augmented by 7-fold by the 
i i • j 
I 
( treatment of secretagogues that mobilized the intracellular calcium, during which the 
i binding of secretin to its receptor and the c A M P increase were not altered (Collen et 
al, 1982). This suggested that the intracellular calcium mobilized from the 
intracellular stores was the major determinant of the activation of secretin receptor by 




1.4 Secretin and autism 
Autism or Autistic Spectrum Disorder (ASD) is a complex pervasive 
neurodevelopmental disorder characterized by impairments in social interaction and 
communication, behavioural stereotypes and a range of cognitive deficits, which are 
inappropriate for the patient's age group. It is a severe form of childhood 
psychopathology first described by Leo Kanner in 1943 (Schreibman, 1988). 
Although a consensus has not been reached regarding its aetiology or its brain 
substrates, a number of hypotheses have been put forward. One early and influential 
speculation suggested that dysfunction of the frontal lobe might underlie some of the 
autistic's characteristic behavioural abnormalities (Damasio and Maurer, 1978). Some 
magnetic resonance imaging (MRI) evidence uncovered the neuroanatomical 
abnormalities in brainstem, cerebellum, frontal lobe, corpus callosum, and limbic 
system in autistic individuals (Courchesne, 1997; Manes et al, 1999; Carper and 
Courchesne, 2000; Riva and Giorgi, 2000). These results indicate that autism is a 
neurological syndrome of brain function with an organic basis. 
In the recent years, secretin has gained much attention as a potential 
breakthrough in the treatment of autism following administration of the hormone to a 
child suffering chronic diarrhea associated with the disease. The story spread widely 
through the internet immediately. Meanwhile, there were some reports supporting the 
idea that secretin has a remarkable effect in reducing specific behavioral components 
of autism (Horvath et al., 1998; Lamson, 2001). These suggested an association 
between gastrointestinal and brain function in patients with autistic behavior, or that 
secretin receptors in the brain are responsible for some of the observed benefits. 
However, some conflicting reports showed that secretin treatment was associated with 




few clinically meaningful improvements compared with placebo (Sandler et al, 1999; 
Owley et al., 1999; Chez et al., 2000; Coniglio et al., 2001; Roberts et al, 2001). Up 
i to now, it is unlikely that autistic patients will be cured by secretin, and there is still 
no consensus on whether secretin is just a placebo in improving autism. Thus the role 




1.5 AMPA receptor 
Glutamate, the major excitatory neurotransmitter in the mammalian central nervous 
system, acts through two broad classes of glutamate receptors: ion channel-linked 
(ionotropic) glutamate receptors (iGluRs), which include N-methyl-D-aspartate 
(NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and 
kainic acid (KA) type glutamate receptors, and metabotropic glutamate receptors 
(mGluRs) which couple via G-proteins to intracellular messenger cascades, the 
phosphatidylinositol (PI) metabolism or adenyl cyclase secondary messenger system 
(Batchelor et al., 1994, Yoneda and Ogita, 1991). Classification of the ionotropic 
glutamate receptors (iGluRs) is based on the differential sensitivity to excitement by 
different agonists, which are all glutamate analogues. The A M P A receptor is an iGluR 
subtype mediating the majority of fast excitatory synaptic transmission in the 
mammalian central nervous system. 
1.5.1 Molecular biology 
As an iGluR subtype, the A M P A receptor is actually an integral ligand-gated cation 
channel which is permeable to Ca++ and Na+. Currently four genes (GluR-A, -B, -C 
and -D) are known that encode for the four A M P A receptor subunits, namely the 
GluRl, GluR2, GluR3, and GluR4 (Schoepfer et al., 1994). These subunits exist as 
two splicing variants, flip and flop. The functional A M P A receptor is believed to be a 
heteromer comprising a combination of the four closely related subunits, GluRsl-4 
(Bettler and Mulle, 1995). Diversity of the A M P A receptors is obtained through 
multiple combinations of the four A M P A receptor subunits, by alternative splicing of 
subunits at the flip/flop and/or C-terminal sites, and by m R N A editing of a single 
amino acid at multiple sites (Lee et al., 1998). 
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In 1989, a complementary D N A of about 3kb clone was first isolated by 
screening a rat brain c D N A library. This c D N A encodes a single protein GluRl of 
relative molecular mass 99,800 which on expression in Xenopus oocytes actually 
forms a functional homomeric AMPA-gated ion channel possessing the 
electrophysiological and pharmacological properties of the A M P A subtype of the 
glutamate receptor family in the mammalian central nervous system (Hollmami et al, 
1989). Other genes for A M P A receptor subunits, GluR2, GluR3, GluR4 were also 
cloned and each protein encoded by the individual genes forms a homomeric ion 
channel with binding sites for A M P A on the single receptor polypeptides (Boulter et 
al., 1990; Fletcher et al, 1995). 
The individual A M P A receptor subunits are approximately 900 amino acids in 
r.t" 
length, and show approximately 65-75% sequence homology between subunits 
(Hollmann and Heinemann, 1994). Each of the subunits consist of three 
transmembrane domains (Ml, M 3 , M 4 ) and one re-entrant loop within the membrane 
(M2) (Bennett and Dingledine, 1995). It is thought that the M 2 loop participates in the 
formation of the ion channel pore. Two 150 amino acid sequences (SI and S2) which 
are separated by the M1-M3 membrane domains appear to represent the agonist 
recognition sites (Keinanen et al., 1997). 
1.5.2 Localization 
A M P A receptors, including the four subunits, are widely distributed in nearly all the 
regions in the mammalian central nervous system, such as the cerebral cortex, basal 
ganglia, limbic system, thalamus, cerebellum, brainstem and spinal cord (Conti et al., 
1994; Martin et al., 1993; Nagy et al., 1994). Western-blot analysis using antibodies 





] membranes of the rat hippocampus and cerebellum associated with postsynaptic 
I 
！ densities. Although glutamate receptors are thought to be the most prevalent 
I 




j reveals that the A M P A receptors are localized predominantly in neurons of the 
I 
j cerebellum and some structures of the limbic system, including the hippocampus, the 
i 
_ . 
I central nucleus of the amygdala, and portions of the septum. This pattern of 
I 
！ expression is, in general, consistent with the distribution of GluRl m R N A as 




j 1.5.3 Pharmacological property 
, The pharmacology of the ionotropic glutamate receptor subtypes is clearly different 
‘ from each other. [^H]AMPA binding displays pharmacological profiles of the A M P A 
I 
i subtype receptor with a rank order of agonistic potencies of quisqualate (QA) > 
i 
i A M P A = domoate > glutamate > kainate (KA), which is apparently different from 
: that found for the K A receptor (domoate >= K A > Q A > glutamate) (Yoneda and 
\ Ogita, 1991). Both the A M P A and K A receptors are not sensitive to N-methyl-D-
I 
: Aspartate (NMDA), and hence belong to the non-NMDA receptors (Bochet and 
！ Rossier, 1993). Agonist-activated inward currents through A M P A receptors 
， 
‘ desensitize rapidly for A M P A , quisqualate, glutamate and to a limited degree for 
i 
J Kainate as an agonist. 
I 
£ 
！ Until now, the competitive antagonists of choice for A M P A receptors have 
E • 
； been the quinoxalinediones such as 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), 6-
I 
； nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione (NBQX), and 6,7-dinitroquinoxaline-
\ 2,3-dione (DNQX). However, these compounds also have significant inhibitory 
i 
I 








I discriminate between A M P A and kainate receptor subtypes (Blealonan and Lodge, 
i 
I 
• 1998). Recently developed 2,3-benzodiazepines, such as GYKI52466 and 
I 
I GYKI53655 (LY300168) provide selective and non-competitive antagonism of 
I 
A M P A receptors. These compounds inhibit the A M P A receptor-mediated responses 
with relatively low potencies and show a relatively high degree of selectivity for 
i A M P A receptors vs kainate receptors (Wilding and Huettner, 1995; Blealonan et al., 
！ 1996). In addition, SYM2206 ((±)-4-(4-aminopheny 1)-1,2-dihydro-1 -methyl-2-
• 
I 
I propycarbamoyl-6,7-methylenedio-xyphthalazide) has also been reported to be a 
i 
； potent non-competitive and specific A M P A receptor antagonist working at the same 
• 
I 
； site as the 2,3-benzodiazepines (Pelletier et al., 1996). 
1.5.4 Function 
As well known, postsynaptic A M P A receptors play a fundamental role in synaptic 
I ？ transmission in the central nervous system (Jonas, 1993), where they mediate an 
： almost ubiquitous component of excitatory synaptic currents (Lukasiewicz et al., 1997) 
• 
i and where they participate in diverse processes such as neuronal plasticity (Kullmann 
I 
5 et al., 2000) and neurotoxicity (Schousboe et al., 1994). 
j By contrast, the physiological significance of presynaptic A M P A receptors has 
not been well documented, except for some scattered reports. For examples, glutamate 
: acting on presynaptic A M P A receptors reduces the amplitude of evoked inhibitory 
j postsynaptic currents recorded from Purkinje cells in the cerebellum, attenuating the 
I 
‘ efficacy of inhibitory transmission from the interneurons onto these Purkinje cells 
； (Satake et al., 2000); Dopamine (DA) release from nerve terminals of the nigrostriatal 






regulation mediated directly by the presynaptic N M D A and A M P A receptors 

















The cerebellum is a transversely fissured neuron mass in the central nervous system 
j 
1 tissues attached to the dorsum of the brainstem by peduncles and occupies most of the 
j 
I posterior cranial fossa. It is composed of an outer mantle of gray matter (the 
i j 
I cerebellar cortex), internal white matter, and deep nuclei that project out of the 
j 
I 
I cerebellum. The cerebellum has connections with all the other regions of the brain and 
I 
1 I 
I plays an important role in motor control, coordination of movements, cognitive 
！ j 






1.6.1 Structure of the cerebellar cortex 
The cerebellum has a very uniform and stereotyped structure with geometrical 
precision. It is covered by a four-layered cortex and contains the deep cerebellar 
nuclei within its central white matter. The four layers of the cerebellar cortex are quite 
I obvious and relatively uniform in appearance, in histological sections cut in any plane 
perpendicular to the pial surface. The superficially situated layer that contains many 
scattered small neurons (basket and stellate cells) is the molecular layer. Next is the 
Purkinje cell layer composed of the large somata of Purkinje neurons strung out in a 
monolayer. Beneath the Purkinje cell layer is the granular layer, composed of the very 
densely packed somata of small neurons, the granule cells, and the somata of some 
scattered larger neurons, the Golgi cells. Beneath the granular layer is the medullary 
layer, composed mostly of myelinated afferent fibers of extracerebellar origin that 
terminate in the cerebellar cortex and efferent fibers of cerebellocortical origin that 
terminate mostly in the cerebellar deep nuclei. 
20 
1.6.2 Neurons of the cerebellar cortex 
1.6.2.1 Granule cells 
Granule cells are the smallest and by far the most numerous neurons of the cerebellar 
cortex. The nucleus of granule cells is surrounded by a thin cytoplasm and billions of 
the cell bodies are packed densely in the granular layer. Each granule cell has 3-5 
dendrites which terminate in the region named glomeruli in the molecular layer, 
where contact is made with enlarged excitatory mossy fiber endings (called rosettes) 
and the terminals of other axons like the inhibitory Golgi cell axons. The initial 
vertical portion of the granule cell axon passes through the granular and Purkinje cell 
I layers and, upon reaching a particular level in the molecular layer, bifurcates there to 
form the horizontal portion of the axon, known as the parallel fiber that is excitatory 
i [ 
via releasing the excitatory neurotransmitter, glutamate. The overwhelming majority 
i 
I of parallel fiber synapses are made with the dendrites of Purkinje cells compared with 
I basket, stellate and Golgi cells (Palkovits et al., 1971; Pitchitpornchai et al., 1994). 
i 
Because all the neurons contacted by parallel fibers (basket, stellate, Purkinje and 
Golgi cells) are inhibitory neurons, the net effect of granule cell excitation is the 
I 
inhibition of discharges by their target neurons. 
1.6.2.2 Purkinje cells 
The most prominent neurons in the cerebellar cortex are Purkinje cells because of 
their large sizes of the somata and the distinctive monocellular dispersal between the 
molecular and granular layers. Each of them has an extensive dendritic arbor aligned 
within the molecular layer and a single axon that traverses the granular layer, more or 
less perpendicularly to the cortical surface. Before the axon joins the medullary layer 




below or above the Purkinje cell layer. These recurrent collaterals synapse with other 
Purkinje cells, or Golgi and basket cells. The primary targets of the Purkinje cell axon 
are neurons in the cerebellar deep nuclei, and particularly the superior and medial 
vestibular nuclei (De Zeeuw et al., 1994; Xiong and Matsushita, 2000). 
I The Purkinje cell, which provides the unique output from the cerebellum, 
i 
I receives two excitatory inputs: one input is originated from the mossy fibers, which is 
relayed by granule cells and their axons, parallel fibers, and the other is from climbing 
I fibers which originate at the contralateral inferior olivary nuclei. Estimates of the 
I 
! 
number of Purkinje cells contacted by a single parallel fiber vary from 225 to 750 
(Palkovits et al., 1971; Brand et al., 1976). While it is believed that one parallel fiber 
makes only a single contact with a particular Purkinje cell, it has been estimated that 
200,000 or more parallel fibers cross the dendritic arbor of a single Purkinje cell 
through the depth of the molecular layer (Eccles, 1967). Excitation by thousands of 
parallel fibers simultaneously could bring the membrane potential of Purkinje cells to 
the threshold of firing. The mossy fiber-parallel fiber afferent system triggers the so-
called simple spikes that typically discharge in a tonic fashion with high frequency 
I (65/sec) bursts, whereas the climbing fibers elicit the complex spikes that discharge 
irregularly at a very low frequency and consist of a short latency initial large spike 
followed by a ripple of small spikes (Thach, 1970). 
I The excitation of Purkinje cells produces inhibition in its target structures, by 
i releasing the major inhibitory neurotransmitter G A B A from the axon terminals, others 
include taurine. There are also powerful inhibitory effects exerted on Purkinje cells by 









1.6.2.3 Basket and stellate cells 
Basket and stellate cells are two types of small interneurons present in the molecular 
layer. The soma of the basket cell is situated in the lower one third to one half of the 
molecular layer close to the Purkinje cell layer, while that of the stellate cell is located 
in the upper two-thirds of the molecular layer. Both types of interneurons are 
GABAergic and constitute the major inhibitory input to Purkinje cells (Vincent et al., 
1992). They receive an excitatory input from the parallel fibers and their major 
inhibitory input from other basket and stellate cell axons (Palay and Chan-Palay, 
1972). Although basket cells might receive a GABAergic input from Purkinje cell 
axon collaterals in addition to the GABAergic input from other basket and stellate 
cells, the synaptic physiology of basket and stellate cells has numerous features in 
common (Llano and Gerschenfeld, 1993a). Basket cells excited by parallel fibers 
exert a powerful inhibitory influence on the spontaneous or triggered discharge of 
Purkinje cells via G A B A (Vincent et al., 1992). 
1.6.2.4 Golgi cells 
The large somata of Golgi cells are situated in the granular layer. Their dendrites 
arborize mostly in the molecular layer and the profusely collateralized axons ramify in 
the granular layer. The dendrites of Golgi cells are contact by the excitatory synapses 
of parallel fibers in the molecular layer and their axon terminals interdigitated with 
the terminals of mossy fibers in the glomeruli of the granular layer, are inhibitory via 
G A B A release (Ottersen et al., 1988). The somata of Golgi cells may also receive 
inhibitory input from Purkinje cell axon collaterals that contact them. 
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I ( 
‘ 1.6.3 Intrinsic circuitry of the cerebellar cortex 
Figure 1.2 summarizes the current understanding of the cytological organization and 
、 1 
functional circuitry of the cerebellum. There are two large afferent (input) systems of 
i 
extracerebellar origin, the climbing fibers and the mossy fibers. Both of them are 
I 、； 
i excitatory. The cerebellar cortex has five major classes of intrinsic neurons as 
1 •j 
described in the last section. The granule cells are the only excitatory intrinsic neurons 
I 
i of the cerebellar cortex. Through synaptic contacts made by their axons, the parallel 
！ fibers, granule ceils excite Purkinje cells, basket cells, stellate cells and Golgi cells, all 
I I of which have their dendrites distributed in the molecular layer. In turn, the basket and 
i 
i 
I stellate cells inhibit the Purkinje cells; and the Golgi cells inhibit the mossy fiber-
j 
granule cell synapse in the glomeruli of the granular layer. The Purkinje cells, basket 
and stellate cells have their dendrites and axons spread in the translobular plane (short 
axis of the folium), and the orientation of the axon collaterals of climbing fibers are 
； similarly in the translobular plane. In contrast, the mossy fiber influence is exerted in 
the parlobular plane (parallel to the long axis of the folium). The axon of Purkinje 
cells are the major efferents from the cerebellar cortex and this output is inhibitory in 
I nature. Purkinje cells inhibition is exerted on neurons of the cerebellar deep nuclei 
j and a few extracerebellar structures, particularly the vestibular nuclei. Because the 
{ inhibitory nature of Purkinje cell action, its direct stimulation by climbing fibers or 
I mossy fibers produces inhibition and its indirect inhibition by way of stellate, basket 
i 
and Golgi cells produces disiiihibition. Since the deep neurons are the only major 
output line from the cerebellum to extracerebellar structures, the superimposed 
; cerebellocortical system can be conceptualized as one exerting a complex modulatory 
i 




i . f 崎 。 - t I 
S • 夺 ； ^ C l e a n s - A 
S J - C ^ - ^ c e n s . 游 ？ / 
I^ Cl：^^. - ^ cells \ V 0 Q I 
i « I 
a neurons 三 罵 F | , 
二 ：：^^二：^广二二：^!^^：^? 1 1 A 
'i \ I I 
: C E L L AND FIBER' . ® ® ® ® ‘ ® ® , 
STAINING ^ — 
TECHNIQUES GOLGI TECHNIQUE AND PHYSIOLOGICAL DATA 
Figure 1.2 The distribution and orientation of the principal cerebellar neurons, their 










METHODS AND MATERIALS 
2.1 Brain slice preparation and maintenance 
Experiments were performed using 12 to 14 days old Sprague-Dawley rats of either 
,i 
i sex supplied by the Animal House of our university (CUHK). The rats were firstly 
sacrificed by decapitation. Then the brains were rapidly removed and immediately 
i placed in ice-cold artificial cerebral spinal fluid (ACSF). The artificial cerebrospinal 
fluid (ACSF) contains, in m M : 2 KCl, 120 NaCl, 2 MgS04, 12 KH2PO4’ 26 NaHCOs, 
2.5 CaCli, 11 glucose, bubbled with carbogen. Cerebellar slices (see Figure 2.1) with 
i 
200 to 250 |Lim thickness containing Purkinje cells (PC) were prepared by a vibrating 
microtome (Campden Instrument, U.K.) (Hausser et al., 1995; Ye et al., 1997). They 
were maintained at 35 士 1 °C in ACSF for at least 30 minutes before experiments 
(Edwards et a/., 1989; Stuart et al,1993). During an experiment, a slice was 
i I transferred to a small volume (〜0.5 ml) superfusion chamber that was mounted on an i 
I ’ 
upright microscope (Zeiss Axioskop). The slice was pinned down under a nylon grid 
！ ！ 
j C-ring and was continuously superfused with the ACSF at a rate of 1.5 to 2 ml/min. 
1 I 
I The temperature of the ACSF in the recording chamber was maintained at 34 ± 1 °C 
i 





2.2 Experimental set-up 
2.2.1 Visualization of neurons 
Neuronal somata and proximal dendrites of neurons were visualized by a combination 
of differential interference contrast (DIC) optics and contrast-enhanced infrared video 
microscopy (hammamatsu video camera C2400-07) following the method described 
by Stuart, et al (1993). The DIC optics allows optical sectioning of the slices while 
the use of infrared light facilitates penetration into the slices. The Purkinje cell (PC) 
layer on the loops of the cerebellar slices consisting of a high density of large Purkinje 
neurons could be easily identified. Cells were selected in the regions of these PC 
layers (see Figure 2.1). Normally, recordings were made from those intact and smooth 
neurons that were found as near the top surface as possible. The appearance of a 
typical Purkinje neuron projected onto the video monitor is shown in Figure 2.2. 
2.2.2 Electrophysiological recordings 
Whole-cell patch clamp recordings were obtained using a conventional patch-clamp 
amplifier (List Electronics). A neuron was first identified and then approached under 
visual guidance. A positive pressure of about 80 mbar was applied to the pipette to 
clear the way and to clean the membrane surface (see Figure 2.2). Whole-cell 
recordings were achieved by first forming a gigaohm seal between the whole-cell 
pipette and the membrane of the neuron and thus isolating a patch of membrane. By 
rupturing the patch through a strong suction, whole-cell access would be established 
allowing recordings of the current flowing across the entire cell membrane in voltage-
clamp and of membrane potential changes in current-clamp (Hamill et al, 1981). 
I 
Recording pipettes were pulled from borosilicate glasses by a pipette-puller (Sutter 
Instrument) and usually had resistances from 2.2 to 5 M Q when containing the 
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Figure 2.1 A photo under the microscope at low magnification showing the 
appearance of the Purkinje layer on a cerebellar slice. The Purkinje neurons are 
arranged closely on the PC layer (P) indicated by arrows. Beside the PC layer are the 
molecular cell layer (M) and granular cell layer (G) respectively. 
5 0 |Lim 
Recording electrode \ 
Purkinje neuron 
Figure 2.2 A picture taken with a thermal video printer using differential 
interference contrast and infra-red video microscopy showing the appearance of the 
cell body and dendrites of a Purkinje neuron. The soma size of this neuron is 
approximately 30 x 40 ^im. The depression at the center of the soma is the result of 
positive pressure applied to the recording pipette to clean the membrane surface 
before making a seal. 
internal solution with the following compositions (in mM): 140 KCl, 2 Nai-ATP, 2 
MgCl2, 10 HEPES, 1 E G T A . To ensure that G-protein mediated effects were not 
impaired, G T P (0.4 m M , from Sigma) was freshly added to the internal solution 
before experimentation. The pH was adjusted to 7.3 with K O H . The liquid junction 
potential was not corrected in m y experiments. Series resistance was checked 
periodically and typically had values around 15 M Q . The series resistance was not 
compensated but the recording was abolished when its value changed significantly (> 
15%) during an experiment. Spontaneous and TTX-resistant miniature inward 
synaptic currents were largely abolished by bicuculline methiodide (10 \xM), 
indicating that they were G A B A A receptor-mediated. 
The membrane current signal was filtered at 3 or 5 kHz and was taped using a 
D A T recorder (SONY) modified for recording A C and D C signals at a sampling rate 
of 32 kHz. Data were captured on-line or off-line by the Digidata-pClamp package 
(Axon Instrument) or CED-Patch and Voltage Clamp Software Package (Cambridge 
Electronics Design). Pulsed protocols were generated via the C E D 1401 plus interface. 
The current-voltage relationship of a neuron was determined by applying 
voltage ramps generated from the Digidata-pClamp package or C E D software and 
interface. The ramp pulses were usually from -140 m V to -40 m V lasting 100 ms. 
The average of 100 — 150 current-voltage curves were obtained before and after 
addition of drugs. The current-voltage relationship of drug-activated conductance was 
then generated by subtracting these two averages from one another. 
2.2.3 Evoked stimulation 
Evoked postsynaptic currents could be elicited by applying single shock (< 0.5 ms, < 
99 V, repeated at least every 5 s) of electrical stimulation delivered via a monopolar 
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pipette (tip size < 100 [xm) filled with ACSF (See Figure 2.3). In most cases, the 
stimulation pipette had to be placed in several different locations before a consistent 
synaptic current could be observed. Fifty to one hundred consecutive responses were 
averaged for analysis. During some experiments in which the presynaptic modulation 
of the IPSCs was studied, identical paired stimuli (interpulse interval of 50 ms) were 
given every 4 s. To evoke inhibitory synaptic currents, 6-cyano-7-nitroquinoxaline-
2,3-dione (CNQX, 2 0 | l iM) and (±)-2-amino-5-phosphonopentanoic acid (APV, 50 
|j,M) were added to the ACSF and currents were passed from an ACSF-containing 
pipette in the molecular layer located 50 - 200 |Lim from the recording neuron. To 
evoke EPSCs, bicuculline (10 fiM) was added in the ACSF. EPSCs originating from 
the parallel fibre were identified based on their property of paired-pulse facilitation. 
2.2.4 Drug preparation and administration 
A drug was applied by changing the pure superfusing A C S F to one added with a 
known concentration of the drug. Before exchange, the solution containing drugs was 
well bubbled with carbogen. The delay of the superfusion system, including the time 
for heat exchange, was about 30 s. 
Drugs were obtained from the following sources: rat secretin (Novabiochem); 
forskolin, C N Q X , A P V , bicuculline methiodide (RBI); SQ22536, A M P A , kainic acid, 
I B M X , H-89, Bisindolymaleimide I (Calbiochem); SYM2206, SYM2081 (Tocris); 
VIP, P A C A P , cadmium chloride, Tris-GTP (Sigma); T T X (Alomone's Lab). Most of 
these compounds were prepared as concentrated stocks by dissolving in D M S O or 
distilled water, and were diluted in ACSF just before use to the final concentrations 
described in appropriate sections. 
28 
Recording electrode 
\ Stimulating electrode 
1 mm 
Figure 2.3 Synaptic currents were evoked by placing the stimulating electrode on 
the surface of the cerebellar slice and in the molecular layer located some distance (50 
—200 |im) from the recording electrode so that afferent fibres to the neuron were 
activated without directly stimulating the neuron itself. 
2.3 Data analysis 
2.3.1 Construction of dose-response curve 
Dose-response curves were constructed using SigmaPlot (Jandel Scientific) based on 
the equation: I = Imax / (1 + EC50 / Dose). Using this equation, the EC50 was estimated. 
2.3.2 Analysis of synaptic currents 
Automatic detection and analysis of the spontaneous and miniature IPSCs were done 
by a home-grown software developed by Dr. W.H. Yung. This program, written in 
Delphi (version 2, Borland), employs a simple detection algorithm described in detail 
by Vincent and Marty (1993). Briefly, a synaptic current is detected when the 
difference between the averaged currents within two brief periods of time, separated 
by a time gap, exceeds a threshold. The length of these time periods is adjustable and 
typically less than 1.4 ms. Once a synaptic current is detected, information on the time 
of occurrence and peak amplitude are generated automatically. Other functions of the 
program include averaging of spontaneous synaptic currents, fitting of the decay of a 
synaptic current with a mono-exponential function using a least square algorithm, 
generation of histogram and cumulative probability distributions, and statistical 
comparison of two cumulative probability distributions using the Kolmogorov-
Smirnov (K-S) test. All detected events with the computed parameters are allowed 
visual inspection for acceptance or rejection. Figure 2.4 illustrates some of the 
functions of the program. 
2.3.3 Statistics 
i 
I Numerical data are expressed as mean 士 S.E.M. Comparison of the amplitude 
distributions and inter-event intervals of IPSCs before and after drug treatment was 
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Figure 2.4 Snapshots taken during the execution of the synaptic current analysis 
program. In the upper panel, the results of automatic detection of miniature IPSCs are 
summarized and reported on screen. In the lower panel, the window on the left 
isolated a single IPSC indicating the baseline, peak and half decay time. The data are 
transformed semi-algorithmically allowing fitting of the decay using a least-square 
algorithm. The red trace is the averaged waveform from manually accepted IPSCs. 
I 
I made by applying the Kolmogorov-Smirnov test using a probability (P) of 0.05; 
1 _ I 
otherwise statistical tests were based on Student's paired or unpaired Mests, as 
appropriate. 







3.1 Basic characteristics of IPSCs recorded from PCs 
3.1.1 Spontaneous IPSCs 
As previously reported (Zhang et al., 1999), spontaneous IPSCs were recorded from 
Purkinje neurons in the presence of glutamate receptor antagonists AP5 (20 |LLM) and 
C N Q X (20 jj,M) in the saline bathing the cerebellar slices. When voltage-clamped at -
70 m V , spontaneous inward synaptic currents ranging widely in amplitude from 〜20 
to 〜2000 p A appeared at random with a very high frequency (> 5.0 Hz usually). The 
majority of these spontaneously occurring currents were blocked completely by 10 
J A M bicuculline (Figure 3.1), indicating that they were mediated by G A B A A receptors. 
When IPSCs were recorded, 140 m M KCl was included in the recording pipettes 
which enhanced inward going IPSCs detection presumably by increasing the driving 
force on the CI ions. As are typical of other fast synaptic currents, these IPSCs are 
characterized by a steep rising phase and a much slower decay time course. The decay 
phase of many spontaneous IPSCs could be approximated by a mono-exponential 
function (Figure 3.2). In the present study, the decay kinetics was measured by ti/2, the 
time required for the peak current to decay to half its value, which does not assume 
the decay to follow any particular function. The distributions of amplitude, rise time 
and ti/2 of a typical Purkinje neuron are shown in Figure 3.3. The mean values of the 
spontaneous IPSC amplitude and frequency collected from 11 Purkinje neurons are 
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Figure 3.1 When voltage-clamped at -70 m V and in the presence of APS and 
C N Q X , spontaneous IPSCs were observed in the Purkinje neuron as shown in the 
upper trace. The lower trace illustrates that these IPSCs were G A B A a receptor-
mediated because they could be abolished by 10 |xM bicuculline. 
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Figure 3.2 Upper: an individual spontaneous IPSC recorded from a Purkinje neuron 
showing typical kinetics. Lower: semilogarithmic plots of the time course of the 
corresponding IPSC. Visual inspection and least square fits to the straight-line 
portions of the plots illustrate that the IPSC is adequately described by the mono-
exponential function. The rise time and decay time (ti/2) of this IPSC were 1.5 and 5.9 
ms respectively. 
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Figure 3.3 Distributions of the amplitudes, rise times and decay times (ti/2) of 
spontaneous IPSCs recorded from a typical Purkinje neuron. Spontaneous IPSCs with 
small amplitudes appear more frequently than those with large ones. In this neuron, 
the mean values of amplitude, rise time and tm were 265.8 土 481.0 pA, 1.17 士 0.71 ms 
and 6.03 土 5.09 ms. 
I 
3.1.2 Miniature IPSCs 
Previous studies (Llano and Gerschenfeld, 1993; Zhang et al., 1999) have reported the 
persistence of spontaneous synaptic activities in Purkinje cells in the presence of 
tetrodotoxin (TTX). However, the quantification of the effects of T T X on 
spontaneous IPSCs was not very consistent. W e found that bath-applied T T X at 0.5 
jaM was sufficient to block all the action-potential dependent activities in Purkinje 
neurons in our preparation (Figure 3.4). At the same time, T T X abolished about 80% 
of synaptic events in the neuron shown in Figure 3.4, confirming the large population 
of action-potential dependent G A B A release from inhibitory interneurons and 
revealing spontaneous basal G A B A release from nerve terminals. Thus, by comparing 
the differences of the characteristics of the IPSCs before and after addition of TTX, 
the general properties of the action-potential dependent and action-potential 
independent IPSCs can be characterized. After T T X (0.5 |iM) was added, there was a 
marked reduction in both the amplitude and frequency of the events. In the 11 
Purkinje neurons tested, the mean frequency and amplitude of the spontaneous 
synaptic currents were reduced by T T X from 16.9 Hz and 129.7 pA to 2.54 Hz and 
75.8 pA respectively as summarized in Figure 3.5. In the presence of TTX, the 
amplitude of the TTX-resistant, or miniature IPSCs usually ranged from 〜20 to 〜700 
pA and the frequency was from 〜2.0 to 〜5.0 Hz, at a holding potential of-70 m V , 
They were both very variable among different cells. 
3.1.3 Evoked IPSCs 
In the presence of 20 ^ iM APS and 20 ！iM C N Q X , IPSCs in Purkinje cells could also 
be evoked in response to electrical stimulation through an electrode placed in the 
molecular layer on the cerebellar slices, as described by Mitoma et al, (1994)。The 
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Figure 3.4 A typical experiment showing the effect of TTX on spontaneous IPSCs. 
Application of 0.5 p M TTX eliminated a significant portion of spontaneous IPSCs 
and this effect is hard to be washed out. In this cell, recovery from the effect of TTX 
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Figure 3.5 Histograms summarizing the effect of T T X on spontaneous IPSCs in 11 
Purkinje neurons. Miniature IPSCs were recorded in the presence of 0.5 [xM TTX. 
Application of T T X decreased both the IPSC amplitude and frequency. * P < 0.05; 
*** P < 0.001. 
evoked IPSCs were very similar to the spontaneous IPSCs in that they were 
characterized by a steep onset usually separated from the stimulation artifact by 
several ms, and a slower decay back to the baseline. Routinely, groups of 50 
individual consecutive evoked IPSCs were sampled and averaged. Like the 
spontaneous IPSCs, all the evoked IPSCs were blocked by l[iM bicuculline and 
therefore mediated by G A B A A receptors. Generally, evoked IPSCs had much larger 
amplitude (> 1000 pA) than the spontaneous IPSCs as shown in Figure 3.6. The 
decaying phase of most evoked IPSCs could also be well approximated by a mono-
exponential curve. 
3.1.4 Rundown of IPSCs 
The in vitro Purkinje neurons in the cerebellar slices were very robust in viability。 
Thus IPSCs recorded from them were very stable and long lasting. According to the 
experiments, IPSCs in Purkinje neurons did not run down significantly within at least 
one and a half hours, sometimes even much longer. This was beneficial to our 
experiments in which the application and washout of drugs may take a long time. 
3.2 Electrophysiological effects of secretin 
As there had been no report on the function of secretin in C N S as a neuropeptide, 
whole-cell patch clamp recordings were performed from Purkinje cells to explore the 
possible in vitro electrophysiological effects of secretin. W e concentrated on the 
Purkinje cells in the rat cerebellar slices because it has been well documented that 
secretin is present and bioactive in the brain especially in the cerebellum (O'Donohue 
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Figure 3.6 Secretin facilitates GABAergic synaptic transmission in the rat 
cerebellum. Raw traces shows that evoked IPSCs recorded from Purkinje neurons 
were augmented by bath application of 30 n M of secretin. Paired-stimuli (arrows), 
separated by a 50 ms interval, were given every 4 s. Four overlaying traces are plotted 
in each case. 
—70 m V to insure that enough large and numerous IPSCs were recorded. Secretin at 
different concentrations was applied directly into the bath. Secretin (3 - 300 n M ) did 
not cause any observable change in the holding current or membrane excitability of 
Purkinje neurons. Thus we focused on examining the effects of secretin on the 
; spontaneous, miniature and evoked IPSCs originating from interneurons, and the 
excitatory postsynaptic currents (EPSCs) originating from parallel fibres in the 
molecular layer in cerebellum. 
3.2.1 Effects of secretin on evoked IPSCs and EPSCs 
In the first series of experiments, the action of secretin on evoked IPSCs and EPSCs 
was studied in Purkinje cells. Since many postsynaptic receptors including G A B A B 
receptors and the putative secretin receptors are G-protein coupled, GTP was always 
included in the recording pipette freshly. In voltage-clamp recordings, a brief (3 - 5 
min) exposure to secretin (3 - 300 n M ) resulted in a clear increase in the amplitude of 
the evoked IPSCs in Purkinje neurons (Figure 3.6). These actions of secretin were 
always reproducible. Usually they had an onset latency of 1 - 2 min in our system and 
were long lasting, typically required more than 30 min for complete recovery. In 
many cases the actions of secretin on IPSCs were too strong to be washed out in more 
than one hour. As shown in Figure 3.7, the action of secretin was specific to IPSCs 
since the EPSCs evoked by stimulating the parallel fibres were not affected by 
secretin (100.0 士 0.5 % of control; n = 4). In 7 cells tested, 30 n M secretin increased 
the amplitude of the evoked IPSCs to 180 士 23 % of control (P < 0.001). However, 
secretin did not alter the latency, rise-time and decay kinetics of the IPSCs (Figure 
3.8A), suggesting that the potentiation was not due to the recruitment of additional 
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Figure 3.7 Secretin facilitates GABAergic, but not glutamatergic, synaptic 
transmission in the rat cerebellum. A, Averaged traces from 50 evoked IPSCs and 50 
evoked parallel-fibre (PF)-PSCs. The amplitude and waveform of PF-PSCs were 
unaffected by 30 n M secretin, in sharp contrast to the evoked IPSC. Mean data of the 
effect of 30 n M secretin on PF-PSCs and evoked IPSCs are shown in B. The increases 
in the amplitude of control were 180 ± 23 % and 100.0 士 0.5 %• Numbers in the 
brackets denote the sample size. *** P < 0.001. 
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Figure 3.8 Effects of secretin on the paired-pulse ratio of evoked IPSCs. A, the 
normalized IPSCs from the cell shown in Figure 3.6 indicated that the kinetics of the 
evoked IPSCs was not changed by secretin. B revealed a reduction of paired-pulse 
ratio (IPSC2/IPSC1). Numbers in the brackets denote the sample size. * P < 0.05. 
by a consistent reduction in the paired-pulse ratio (Figure 3.8A). In 7 Purkinje cells, 
the mean paired-pulse ratio decreased from 0.86 士 0.04 to 0.82 士 0.04 (P < 0.05, 
Figure 3.8B). 
3.2.2 Effects of secretin on spontaneous IPSCs 
The evoked IPSC is very similar in mechanism with the spontaneous one which 
mainly includes an action-potential dependent component. Thus the action of secretin 
on the spontaneous IPSCs in Purkinje cells was also performed. In this series of 
experiments, the control and effect of secretin were both recorded in presence of 
C N Q X (20 i^M) and the internal solution also included GTP. Similarly, application of 
secretin (3 — 300 n M ) induced a marked increase in both the amplitude and frequency 
�� 
of the spontaneous IPSCs (Figure 3.9). The effect of secretin was long lasting and 
hard to be washed out completely. In 11 cells tested, the frequency and amplitude of 
the spontaneous IPSCs were increased by 30 n M secretin to 221 士 30 % and 162 士 12 
% of control (P< 0.001). 
3.2.3 Effects of secretin on miniature IPSCs 
The increase in the frequency of the spontaneous IPSCs suggested that secretin 
increased the firing of presynaptic neurons. However, in basket cells, this possibility 
was excluded because secretin did not cause any change in the holding current or 
firing rate of these cells (n 二 4). Nevertheless, the reduction of the paired-pulse ratio 
of the evoked IPSCs in Purkinje neurons indicated that the effect of secretin has a 
presynaptic locus of action (Dobmnz and Stevens, 1997; Hashimoto and Kano, 1998). 
Since a change in the frequency of action-potential independent synaptic currents is a 
well-established indicator of the involvement of a presynaptic mechanism (Van der 
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Figure 3.9 Secretin facilitates GABAergic synaptic transmission in the rat 
cerebellum. Raw traces shows that both the frequency and amplitude of spontaneous 
IPSCs recorded from Purkinje neurons were augmented by bath application of 30 n M 
of secretin. Four overlaying traces are plotted in each case. 
Kloot, 1991), the effects of secretin on TTX-resistant, or miniature, IPSCs were also 
examined in Purkinje neurons (n > 100). In the presence of T T X (0.5 |iM), secretin 
consistently increased the frequency of the miniature IPSCs with an onset time of 
about 3-4 min (Figure 3.10). These effects were also very strong and hard to be 
washed out like those on the evoked and spontaneous IPSCs. The effect on the 
amplitude of miniature IPSCs was, however, more variable. For example, at 30 n M , 
secretin increased the IPSC amplitude in 4 out of 8 cells tested (P < 0.05, 
Kolmogorov-Smirnov test). Such increase could be attributed to an increased 
proportion of larger events. In the rest of cells, there was no significant change in the 
amplitude. On average, there was a 10.7 士 6.4o/o (n = 8) increase in the mean 
amplitude of the miniature IPSCs, while a 129.7 士 16.1o/o increase in the mean 
frequency. Figure 3.11 demonstrated the differences of cumulative probability 
distribution curves of miniature IPSCs frequency and amplitude before and after 
application of secretin in a Purkinje neuron which was very sensitive to secretin. 
When various concentrations of secretin were added to a single Purkinje 
neuron orderly from low to high, the effects on both the frequency and amplitude of 
miniature IPSCs would have a very remarkable concentration-response (Figure 3.12 
and 3.13). However, in most cases only a single dose of secretin was added to one 
Purkinje neuron. Due to the variability of increases in the amplitude, a clear dose-
dependent relationship is only apparent in the frequency but not the amplitude, with 
the ECso at about 20〜30 nM. The effects of various concentrations of secretin on these 
parameters (frequency and amplitude) are summarized in Figure 3.14. A low 
concentration (1-3 n M ) of secretin was enough to increase these parameters. 
According to the dose-response curve, 30 n M was chosen to be a suitable 
concentration to further show the effects and mechanisms of secretin. 
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Figure 3.10 Effect of secretin on miniature IPSCs. A typical experiment shows that 
secretin increased the frequency of GABAA-mediated miniature IPSCs. 30 iiM 
secretin was added to the superflision solution for 4 min. Two sets of traces at the 
time points indicated are shown on a fast time-base. In this cell, recovery from the 
effect of secretin took 35 min. 
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Figure 3 .11 Cumulative probability distribution curves of miniature IPSCs recorded 
from a typical Purkinje neuron before and after bath application of 30 n M secretin. 
Filled circles represented control; open circles represented effects of secretin. Secretin 
produced a significant right shift in the distributions of amplitudes (upper curves) and 
left shift in the distributions of inter-event intervals (lower curves) (*** P<0.001， 
Kolmogorov-Smirnov test). These indicated that secretin increased both the amplitude 
and frequency of miniature IPSCs. 
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i Figure 3.12 Raw traces shows the potentiation on miniature IPSCs in a single 
！ 
i Purkine neuron at various concentrations of secretin. A clear concentration-response 
I with respect to both amplitude and frequency could be observed. 
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Figure 3.13 Concentration-response curves in miniature IPSCs recorded from a 
Purkinje neuron, which was very sensitive to application of secretin. The increase in 
frequency was clearly concentration dependent; that in amplitude was concentration 
dependent before it reached 300 nM. 
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Figure 3.14 Concentration-response curve of the effects of secretin on the 
frequency (upper) and amplitude (lower) of the miniature IPSCs. In most cases, only a 
i single dose of secretin was added to one Purkinje neuron. A clear dose-dependent 




These findings indicate that secretin increases the probability of vesicular 
release from presynaptic terminals. This process may contribute to the observed 
potentiation on the amplitudes of the evoked and spontaneous IPSCs by secretin. In 
order to test if the facilitatory effects are specific to secretin, vasoactive intestinal 
polypeptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP), 
two structurally and pharmacologically related neuropeptides in the secretin family, 
were used but these peptides did not produce any effect (10 nM; n = 3 and 6 
respectively). 
3.3 Mechanisms of secretin as a neuropeptide 
The inhibitory synaptic currents including evoked, spontaneous and miniature IPSCs 
in Purkinje cells are all mediated by G A B A A receptors and hence induced directly by 
the G A B A release from interneurons. The results that secretin did potentiate all these 
synaptic currents suggested that secretin may have a presynaptic action site and act as 
a neuromodulator in the cerebellum which facilitates G A B A release onto Purkinje 
cells. To explore the relevant neuronal pathways and mechanisms by which secretin 
exerts its functions, we examined the involvement of the postsynaptic action site, the 
calcium influx, the c A M P second messenger and the presynaptic A M P A receptor in 
the actions of secretin. In these series of experiments, the synaptic currents were 
always recorded at a holding potential of -70 m V and 30 n M secretin was applied 
(see section 3.2.3). W e focused on studying the effect of secretin on the miniature 
IPSCs because in the presence of TTX，the communications between neurons in the 
cerebellum were interrupted and the tested Pukinje cell could be deemed to be directly 
influenced by the presynaptic terminals alone. Thus the problem was simplified. 
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Results were expressed as percentage changes over the control value before addition 
of the drugs. 
3.3.1 Non-involvement of a postsynaptic site of action 
More vesicular G A B A release from the presynaptic terminals induces more IPSCs. 
Thus the increase in the frequency of miniature IPSCs caused by secretin suggested a 
presynaptic site of the action. The potentiation on the amplitude of miniature IPSCs 
which were sometimes observed, however, could also be explained by a possible 
postsynaptic action of secretin. The action may also underlie the observed potentiation 
ill the evoked and spontaneous IPSCs. To address whether secretin may increase the 
amplitudes of IPSCs by increasing the sensitivity of postsynaptic G A B A A receptors 
on Purkinje cells, we compared the inward current induced by exogenously applied 
G A B A in the absence or presence of secretin (30 nM). In all 6 cells tested, the peak 
inward current was not augmented by secretin; instead, a reduction in the amplitude 
was found (Figure 3.15). At this stage, we are not certain of the nature of this 
inhibition. Nevertheless, this finding did not support the notion that secretin has a 
positive modulatory effect on G A B A A receptors. 
As it is well known that secretin receptor is G-protein coupled, an analogue of 
GTP, GDPPs (3 m M ) which competes with GTP and blocks the activation of G-
protein, was used to replace the GTP in the recording pipette to block the activation of 
the putative secretin receptors on Purkinje cells. In all the 4 cells tested, application of 
secretin (30 n M ) still resulted in a clear increase in the frequency of miniature IPSCs, 
and in one of them a clear increase in the amplitude was revealed by applying 
Kolmogorov-Smirnov test on the cumulative probability distributions (Figure 3.16, P 









Figure 3.15. Effect of secretin on postsynaptic G A B A A receptor sensitivity of 
Purkinje cells. A, the inward current induced by exogenously applied G A B A in the 
absence of secretin. B, in the presence of secretin (30 nM). Small volumes (1 ^ il) of 
0.1 m M G A B A were applied directly to the bath at a fixed distance from the recorded 
cell. 
Control with GDPps 30 nM secretin with GDPps 
200pA 
B * 200ms 
10] Control ^  
0.8 _ 
/ / Secretin + GDPps 
丨 r / 
2 0.4- / / 
^ / 
0.2 -
0.0 -M -1 1 • ‘ ‘ 
0 100 200 300 400 500 
Amplitude (pA) 
c 
一 260 1 ^ 120 
O 2 T N S 
C 240- § 110. ———— _ _ X _ _ 
I - r i NS ^ 
° 丁 ^ 1 0 0 -
艺 200 - ^ 
^ 180- •§ 9° -S = 
=16。• & 80. 
140 - 门 
O ^ 70 • 
2 120. (8) ⑷ g (8) (4) 
E 100 E 60 
secretin secretin secretin secretin 
+ G D P + G D P 
Figure 3.16 Effects of secretin on miniature IPSCs were not influenced by GDP(3s 
(3 mM). A, raw traces showing the facilitation of secretin on miniature IPSCs with 
G D P ( 3S in the recording pipette. B , Kolmogorov-Smirnov test on cumulative 
probability distributions in one Purkinje neuron indicated that secretin augmented the 
amplitude of miniature IPSCs. C, histograms summarizing the effects of secretin with 
and without GDPps. * P < 0.05, N S non-significant (P > 0.05). 
9.5 士 1.50/0, which show no significant difference from the effects of 30 n M secretin 
without GDPps. These suggested that the activation of postsynaptic secretin receptors 
was not involved in the action of secretin on both the frequency and amplitude. 
3.3.2 Non-involvement of calcium influx 
Since it has been reported that secretin augments cardiac L-type calcium channel 
currents (Tiaho and Nerbonne, 1996), another series of experiments focused on the 
miniature IPSCs were performed to investigate the possibility that secretin facilitates 
vesicular G A B A release by augmenting calcium influx in the presynaptic terminals. 
2+ 
As illustrated in Figure 3.17, the effect of secretin was not sensitive to 100 luM Cd , a 
broad spectrum blocker of voltage-dependent Ca^ "^  channels. In these experiments, 
Cd2+ was applied to cells 15 mins before adding secretin. In the presence of 100 [iM 
Cd2+, 30 n M secretin increased the mean frequency and amplitude of miniature IPSCs 
to 237.3 士 14.1o/o and 106.1 士 2.3o/o of control respectively in all the tested 5 cells. 
2+ 
These data indicated that miniature IPSCs were facilitated by a Ca influx-
independent mechanism. Even when the cell was preincubated in the calcium-free 
external solution for 15 minutes, the effect of secretin on minature IPSCs was not 
influenced (n = 1), which also suggested that calcium influx was not crucial for 
secretin to exert its facilitation. 
3.3.3 Involvement of c A M P second messenger 
It was well established that secretin increases c A M P concentration in non-neuronal 
target tissues (McGill et al., 1994; Ulrich et al, 1998), and there is also evidence that 
it has the same action in neuronal target tissues (Fremeau et al, 1986, Van Calker et 
al, 1980). To understand the signal transduction pathway of the putative presynaptic 
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Figure 3.17 Ca〗. influx-independent mechanism of secretin-induced potentiation of 
miniature IPSCs in Purkinje cells. A, raw traces showing that the general calcium 
channel blocker Cd^^ at 100 laM did not attenuate the facilitatory effect of secretin (30 
n M ) on miniature IPSC frequency. B, comparison of the cumulative probability 
2+ • 
distributions of frequency in a typical neuron in the presence of Cd . C, histogram 
summarizing the effect of CcP on miniature IPSCs. *** P < 0.001. 
secretin receptor, the involvement of c A M P as the second messenger was examined 
by using SQ22536, an inhibitor of the adenylyl cyclase (Lippe and Ardizzone, 1991), 
H-89, an inhibitor of cyclic AMP-dependent P K A (Chijiwa et al., 1990) and 
bisindolymaleimide I (Bis), an P K C inhibitor (Martiny-Baron et al., 1993). These 
drugs were pre-applied 30 mins before addition of secretin to assure their efficiency. 
As illustrated in Figure 3.18, SQ22536 significantly reduced the secretin-stimulated 
increase in the miniature IPSC frequency from 129.7 土 16.1o/o to 52.5 士 9.4o/o (P < 
0.01; n = 8). H-89 also attenuated the effect of secretin from 129.7 士 16.1o/o to 65.3 士 
17.9% (P < 0.05; n = 8), while Bis did not have the similar inhibition on the action of 
secretin. In the 5 cells tested, Bis did not seem to influence the effect of secretin on 
the miniature IPSCs since a 150.0 士 17.2o/o increase in the frequency was observed (P 
> 0.05; n = 5). These data, which are summarized in Figure 3.18B, indicate that 
2 •卜 • 
increased concentration of intracellular cAMP, but not influx of Ca , underlies the 
facilitatory effect of secretin on IPSCs, and the cAMP-PKA signal transduction 
cascade rather than the P K C pathway, may be an essential component of the action of 
secretin. 
Furthermore, to better demonstrate that the activation of the c A M P second 
messenger pathway is positively correlated with the potentiation on the miniature 
IPSCs, the Purkinje cells were exposed to membrane-permeable drugs that increase 
the intracellular c A M P levels, including the adenylyl cyclase activator forskolin 
(Laurenza et al., 1989) and the c A M P phosphodiesterase inhibitor 3-isobutyl-l-
methylxanthine (IBMX) (Turner et al., 1993). They both mimicked the effects of 
secretin on the miniature IPSC frequency (Figure 3.19, forskolin, 10 fiM, n 二 4; 
I B M X , 100 jiM, n 二 3), which were in agreement with previous studies (Mitoma and 
Konishi, 1999). These results provide additional evidence that the secretin-stimulated 
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Figure 3.18 Involvement of the c A M P second messenger pathway in the facilitation 
of secretin on miniature IPSCs. A, raw traces demonstrating the potentiation of 
secretin on miniature IPSCs with or without the presence of SQ22536, H-89, and Bis. 
B, histogram summarizing the inhibition of SQ22536 and H-89 on the effect of 
secretin. Bis did not have the similar effect. Numbers in the brackets denote the 
sample size. * P < 0.05, ** P < 0.01, N S non-significant. 
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Figure 3.19 Forskolin and IBMX both mimicked the effects of secretin on the 
miniature IPSC in Purkinje neurons. Raw traces illustrated that a brief (3 _ 5 min) 
exposure to these drugs resulted in a clear potentiation. These effects were very 
similar with that of secretin and hard to be washed out in 20 min. 
facilitation on the miniature IPSC is mediated through the activation of the c A M P 
second messenger pathway. However, the data do not exclude the possibility that 
potentiation of the amplitudes of the evoked and spontaneous IPSCs involves 
2+ 
augmentation of calcium influx via modulation of voltage-dependent Ca channels. 
3.3.4 Involvement of presynapitc A M P A receptors 
3.3.4.1 Glutamate-mediated action of secretin 
According to our experiments, the majority of postsynaptic currents in Purkinje 
neurons are mediated by G A B A A receptors since they could be blocked completely by 
10 |j,M bicuculline alone even without the presence of AP5 and C N Q X (see Figure 
3.1). Thus the experiments on secretin-stimulated facilitation in miniature IPSCs 
described in the former sections were all performed only using TTX. However, in 
another series of experiments, with the presence of both T T X (0.5 |LIM) and C N Q X 
(20 jaM), a marked reduction in the secretin-stimulated increase in the miniature 
IPSCs frequency was observed when compared with the former results without 
C N Q X . As demonstrated in Figure 3.20, the mean increase caused by secretin (30 n M ) 
with C N Q X in the miniature IPSCs frequency was 59.7 士 12.9o/o (n = 7), which was 
significantly smaller than that in the experiments without C N Q X . 
It should be noted that even the synaptic currents potentiated by secretin in the 
former experiments without C N Q X could completely be abolished by bicuculline as 
shown in Figure 3.1, and experiments on evoked EPSCs also exclude the possibility 
that secretin can facilitate the glutamate release onto Purkinje neurons. Thus, the 
above data suggested that glutamate might play some role in the action of secretin on 
GABAA-mediated synaptic currents via activating some type of presynaptically 
located glutamate receptors, which are antagonized by C N Q X . In other words, bath 
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Figure 3.20 C N Q X inhibits the action of secretin on the miniature IPSC frequency 
in Purkinje neurons. A, raw traces in a typical neuron which was exposed with C N Q X 
at 20 i^M for 20 min before addition of secretin. B, histogram summarizing the 
inhibition of C N Q X . ** P < 0.01. 
application of secretin to the slices induces the glutamate release from somewhere in 
the cerebellum and these glutamate could facilitate the G A B A release onto Purkinje 
neurons by a presynaptic mechanism. To explore this mechanism, a series of 
experiments were performed to investigate the action of presynaptic A M P A receptors 
on miniature IPSCs in Purkinje neurons. A M P A receptors were the focus because 
they are the most ubiquitous non-NMDA glutamate receptors which can be 
antagonized by C N Q X completely. 
3.3.4.2 Effects of A M P A on miniature IPSCs 
Postsynaptic A M P A receptors are generally believed to mediate excitation of neurons 
by classical membrane permeability changes. Up until now, there have been only a 
few reports on presynaptic effects of A M P A receptor agonists on synaptic currents in 
mammalian brain slices (see Chapter 1.5). In this new series of experiments, A M P A , 
an A M P A receptor antagonist was applied to Purkinje neurons in the cerebellar slices 
for about 5-7 min to examine the action of A M P A on miniature IPSCs. Here the 
bicuculline-sensitive miniature IPSCs were isolated by addition of 0.5 |aM TTX. As 
demonstrated in Figure 3.21, bath application of A M P A (600 n M ) led to an increase 
in the frequency of miniature IPSCs, and meanwhile, a clear postsynaptic inward 
current in Purkinje neurons ranging from 100 pA to 400 pA was induced. The onset 
time of the inward current was very short (usually less than 1 min) and that of the 
increase in the frequency of miniature IPSCs is usually less than 2-3 min. These 
effects were always reproducible and dose-dependent. After A M P A was removed 
from the bath, the frequency of miniature IPSCs and the baseline recovered 
completely in several minutes. In all the 12 cells tested, administration of A M P A at 
600 n M produced a increase of the frequency from 3.05 ± 0.35 Hz to 5.25 ± 0.66 Hz 
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Figure 3.21 Effects of A M P A on mlPSCs and base-line. Raw traces in two typical 
Purkinje neurons show an increase in the frequency of mlPSCs and an inward current. 
These effects had a fast time-course and could be washed out quickly in several 
minutes. 
(p < 0.001 Student's paired t-test) while the amplitude remained unchanged (130.5 士 
8.0 pA to 137.0 士 9.8 pA; p > 0.5) (Figure 3.22). The mean increases in the frequency 
and amplitude were 68.9 士 11.30/0 and 7.1 士 3.4o/o of control respectively. 
If the effects on the frequency of miniature IPSCs were caused by the increase 
in the firing of presynaptic interneurons after activation of "postsynaptic" 
(somatodendritic) receptors, then they should be abolished by TTX. Thus the increase 
in the frequency by A M P A was thought to be a presynaptic effect via activation of the 
A M P A receptors on presynatic terminals. Meanwhile, the postsynaptic inward current 
caused by A M P A suggested the existence of postsynaptic A M P A receptors on 
Purkinj e neurons. 
3.3.4.3 Pharmacological evidence 
To further test the specificity of the action of A M P A receptors on AMPA-induced 
increase in the miniature IPSCs frequency, the Purkinje neurons were pretreated with 
the non-NMDA receptor antagonist C N Q X and specific A M P A receptor antagonist 
SYM2206 (see Chapter 1.5) at 20 [iM 20-30 minutes before application of A M P A . 
These antagonists both abolished the postsynaptic AMPA-induced inward current in 
Purkinje neurons, and meanwhile blocked the increase in the miniature IPSCs 
frequency (Figure 3.23). By using Student's paired t-test, it was demonstrated that in 
the presence of SYM2206 A M P A (600 nM) did not increase the miniature IPSCs 
frequency significantly (3.54 士 0.67 to 4.08 士 0.82 Hz; P > 0.05; n 二 9) even though 
there was a mean increase of 13.7 ± 5.0 % . The results of experiments using C N Q X 
were similar (CNQX: 5.06 士 1.39 Hz; A M P A : 5.27 士 1.54 Hz; p > 0.5; n = 4). These 
data together with those described in the previous sections suggest that in the 
cerebellar cortex, activation of presynaptic A M P A receptors facilitates the 
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Figure 3.22 A M P A increases the frequency but not amplitude of miniature IPSCs 
in Purkinje neurons. A, after addition of A M P A , the cumulated distribution curve of 
inter-event intervals shifted to left, showing that the frequency was increased. B, 
histograms summarizing the effects of A M P A (600 n M ) on the frequency and 
amplitude. *** P < 0.001, N S non-significant. 
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Figure 3.23 SYM2206 and C N Q X inhibit the action of A M P A (600 nM) on 
mlPSCs in Purkinje neurons. A, raw traces, showing that C N Q X (20 _ and 
SYM2206 (20 _ blocked the AMPA-induced inward current completely and 
inhibited the increase in the frequency of mlPSCs. B, histogram summarizing the 
inhibition of C N Q X and SYM2206 on the frequency. •»* P < 0.001 " P < 0.01. 
constitutive G A B A release onto rat cerebellar Purkinje neurons. This pathway may 
underlie a complementary component of the action of secretin. 
The possibility of the involvement of presynaptic kainate receptors, another 
type of n o n - N M D A glutamate receptors which are also antagonized by C N Q X , in the 
secretin-induced increase in the frequency of miniature IPSCs was excluded by using 
their agonist kainic acid and another potent specific agonist SYM2081 (Donevan et 
al., 1998). Superfusion of equimolar kainic acid did not induce any detectable 
changes on miniature IPSCs in Purkinje neurons (n = 3). SYM2081 at 100 \xM did not 
increase the frequency of miniature IPSCs neither (Figure 3.24; n 二 4). By contrast, 
the mean frequency was decreased by SYM2081 to 91.3 士 4.7 % of control. Even 
though we are not sure on the nature of this decrease, it is certain that activation of 
presynaptic kainate receptors would not facilitate G A B A release onto Purkinje 




100 mM SYM2081 
_ _ _ _ _ _ _ 
； ( 卜 h i丨丨’’I n i i H ' 丨:I . ij i 11 I 11 
I I ‘ . i 丨 I ； . i I 
！ ！ ！ i s 






0.8 - ^ g r 
j= 0.6 • 2 
OT $ — ^ Control 
I 0.4 / SYM2081 
0.0   
0 1000 2000 3000 
Inter-event interval (ms) 
Figure 3.24 SYM2081 does not increase the mlPSCs frequency in Purkinje 
neurons. A，raw trace showing no significant effect of SYM2081 on mlPSCs. B, 
comparison of cumulative distribution curves of inter-event intervals showing no 




4.1 Secretin as a novel neuropeptide 
Previous studies on endogenous secretin-like neuroactivity and immunoreactivity in 
mammalian brains (see Chapter 1.2) suggested the possibility of secretin as a 
neuropeptide. Furthermore, the data on RT-PCR, Northern blot analysis, in situ 
hybridization and immuno-histochemistry acquired by our collaborators, Dr. Chow et 
al and Dr. Leung et al. (see Chapter 1.3.2), revealed such a scenario that secretin and 
its receptor are expressed in specific neuronal populations of the rat cerebellar cortex. 
Evidence shows that secretin is only conspicuously expressed in Purkinje cells but not 
in other cells in the molecular and granule cell layers, while secretin receptor is 
expressed in both the basket cells in the molecular layer and Purkinje cells. These 
distinct distribution patterns of secretin and its receptor in discrete neuronal types 
strongly imply that they serve specific neural functions. These data also suggest that, 
in the cerebellar cortex, Purkinje cells synthesize secretin that is targeted onto basket 
cells and Purkinje cells themselves. 
However, the functional study on secretin in the brain has never been 
documented. In this study, we found, for the first time, that secretin facilitated the 
evoked, spontaneous and miniature GABAA-mediated IPSCs in Purkinje cells in the 
rat cerebellum through selectively facilitating GABAergic inputs onto them. So it is 
likely that the source of secretin is Purkinje cells, which express secretin m R N A and 
secretin (see Figure 1.1), and that the peptide acts on its own receptors located on 
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basket cell terminals. These novel actions of secretin, which are distinct from those on 
the endocrine system (Daniel, 1990; Nussdorfer et al., 2000), strongly support the 
hypothesis that secretin serves as a neuropeptide in the rat brain. Although secretin 
was the first hormone discovered in human history, there is still no convincing 
evidence to indicate that secretin, like other related members in the same peptide 
family including P A C A P , VIP, growth hormone releasing factor (GRF), glucagon and 
glucagon like peptide-1 (GLP-1), is also a neuropeptide. Information provided by the 
present thesis may well be the last piece of jigsaw puzzle in order to view a completed 
picture of this family of brain-gut peptides, in terms of their physiology and function. 
4.2 Mechanisms of secretin 
The potentiation in the miniature IPSC frequency, as well as the reduction of the 
paired-pulse ratio of the evoked IPSCs indicates a presynaptic site of action of 
secretin. The increase in the frequency of the spontaneous IPSCs also suggests that 
secretin increases the probability of vesicular release from presynaptic terminals (see 
Chapter 3.2.3). This presynaptic functional locus is consistent with the morphological 
findings that secretin receptor is expressed in the basket cells, and both the soma and 
the dendrites of Purkinje cells are positively immunostained by secretin antibody. The 
Purkinje cells receive inhibitory G A B A release at three subsets of synapses coming 
from the basket, stellate and Golgi cells respectively. Thus we proposed that the 
presynaptic terminals that are facilitated by secretin, come from the basket cells, 
according to the distinct morphological presence of secretin receptors on them. This 
presynaptic process may also contribute to the observed potentiation on the 
amplitudes of the evoked and spontaneous IPSCs by secretin. However, the nature of 
the potentiation in the action-potential dependent IPSCs is more complicated than 
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action-potential independent ones, since without the presence of TTX, excitability of 
any other neuron, which has synapse-connections with the target cell, would influence 
G A B A release from the presynaptic terminals. 
U p to the present, we have not found any postsynaptic component of secretin's 
facilitation of IPSCs, based on the experimental results that the G A B A sensitivity of 
G A B A A receptors are not increased by secretin. Even though the expression of 
secretin receptors in Purkinje cells may imply a postsynaptic site of action of secretin, 
GDPps does not result in any observable change in the potentiation in miniature 
IPSCs, and excitability of Purkinje cells is not affected by secretin. Thus we tend to 
believe that the presynaptic secretin receptors, at least, underlie the major function of 
secretin in the facilitation of IPSCs. In addition, it should be noted that a change in the 
mean amplitude of the miniature IPSCs is not necessarily inconsistent with a 
presynaptic mechanism, as has been demonstrated by the presynaptic effect of N-
methyl-D-aspartate ( N M D A ) in the same synapse (Glitsch and Marty, 1999). For 
example, secretin may lead to the selective facilitation of a subpopulation of terminals 
that are associated with larger IPSC amplitudes. This is also consistent with our 
proposal, that secretin only potentiates G A B A release at the distinct subset of 
terminals coming from basket cells, whereas other terminals coming from stellate or 
Golgi cells are not affected by secretin. 
In addition to previous morphological evidence, our electrophysiological 
experiments provide strong pharmacological evidence on the specificity of 
presynaptic secretin receptors in the action of secretin in the cerebellum. The dose-
response curve of the action of secretin in miniature IPSCs indicates an EC50 at about 
20〜30 nM. And the minimum doses of secretin needed to produce facilitation are at 
nanomolar concentrations (1 — 3 nM). These data support the involvement of secretin 
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receptor only (Di Paolo et al., 1999; Rawlings and Hezareh, 1996). Furthermore, two 
structurally and pharmacologically related neuropeptides in the secretin family, VIP 
and P A C A P do not produce any effect in Purkinje cells at the similar nanomolar 
concentration. This exclude the possibility that secretin exert its action via activation 
of other receptors in the secretin receptor family. 
It has been reported that secretin can modify the permeability of some ion 
channels (see Chapter 1.2.4). However, the potentiation of secretin in miniature IPSCs 
is not sensitive to Cd2+. This result excludes the possible pathway, that secretin first 
induces a change of the excitability of the membrane at presynaptic terminals by 
activation or modification of voltage-dependent calcium channels, and then facilitates 
vesicular G A B A release from terminals. Of course, the data do not exclude the 
possibility that potentiation of the amplitudes of the evoked and spontaneous IPSCs 
involves augmentation of calcium influx via modulation of voltage-dependent 
calcium channels. 
By pharmacological methods, the involvement of c A M P second messenger 
pathway in the action of secretin in facilitating the miniature IPSCs was clearly 
revealed. Our data shows that secretin facilitates G A B A release through increasing 
the intracellular c A M P level in the presynaptic terminals. In this process, the cAMP-
P K A signal transduction cascade rather than the P K C pathway plays an important role. 
These findings are very well consistent with the previous studies on the function of 
secretin and Gs-protein-coupled secretin receptor (see Chapter 1.2.4 and 1.3.3), and 
provide further evidence on the involvement of secretin receptor. A wide range of 
neurotransmitters or neuromodulators appear to produce their diverse metabolic and 
physiological effects in nervous tissue by interacting with specific receptors on target 
cells that regulate the activity of the membrane-bound enzyme adenylate cyclase and 
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ultimately the intracellular levels of c A M P (Greengard, 1981). In this regard, it has 
been proved that, the neuropeptide VIP, which is structurally similar to secretin, 
interacts with specific VIP receptors and stimulates adenylate cyclase in nervous 
tissue, elevating intracellular c A M P levels in discrete regions of rat brain (Quik et al., 
1978; Kerwin et al., 1980; Etgen and Browning, 1983). So it is very likely that 
secretin also serves as a neuropeptide in the brain by an intracellular mechanism 
similar with that of other neuropeptides in the secretin family. Our functional studies 
on secretin provide the direct evidence on this hypothesis. 
Another interesting finding in our experiments is the involvement of glutamate 
and presynaptic A M P A receptor in the action of secretin. C N Q X attenuates the effects 
of secretin on miniature IPSCs, whereas it is proved that secretin does not facilitate 
the glutamate-mediated synaptic currents in Purkinje cells. This data suggest that after 
addition of secretin, there is glutamate release from somewhere in the cerebellar 
cortex, which acts on its own receptor located on some presynaptic but not 
postsynaptic terminals, and then facilitates G A B A release onto Purkinje cells. If this 
is the case, there are still two unsolved questions in this hypothesis. Firstly, where is 
the glutamate released from, under the stimulation of secretin? Secondly, the potential 
functional role of presynaptic ionotropic glutamate receptors (iGluRs) in facilitating 
G A B A release has not been firmly established, despite abundant morphological 
evidence for the presence of iGluRs in the brain. U p to now, we still have not enough 
evidence to answer the first question. However, using pharmacological and 
electrophysiological methods, the second one could be explained. 
Actually, there is recently compelling evidence that presynaptic iGluRs may 
modulate synaptic transmission, even though it has been known for long that iGluRs 
are localized on the postsynaptic membrane mediating excitation of neurons by 
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classical membrane permeability changes. For example, in the cerebellum, it has been 
reported that presynaptic N M D A receptors facilitate the constitutive, action potential-
independent G A B A release onto Purkinje cells (Glitsch and Marty, 1999). In contrast, 
glutamate acting on presynaptic A M P A receptors reduces the amplitude of evoked 
inhibitory postsynaptic currents, attenuating the efficacy of inhibitory transmission 
onto these neurons (Satake et al., 2000). W e have shown here that A M P A , by a 
presynaptic mechanism, augments rather than inhibits GABA-mediated miniature 
IPSCs in Purkinje cells. Meanwhile, we proved that it is the presynaptic A M P A 
receptor that A M P A activated. These presumed presynaptic A M P A receptors were 
associated with the facilitation of secretin on G A B A release onto Purkinje cells, while 
other n o n - N M D A glutamate receptors, such as kainate receptors, are not involved. 
These data together with the previous finding of the potentiating effect of A M P A 
receptors on spontaneous IPSCs, which was considered as resulting from the 
activation of axonal A M P A receptors in stellate cells (Bureau and Mulle, 1998), 
suggest that A M P A receptors are present in the axons of cerebellar interneurons, and 
activation of them may lead to enhancement of G A B A release. Here it should be 
noted that we only proved that activation of presynaptic A M P A receptors play a role 
in the potentiation of secretin in miniature IPSCs, whereas whether it also plays the 
same role in the secretin-induced potentiation in spontaneous and evoked IPSCs, is 
still unknown. 
Based on our current understanding, two models describing the intracellular 
and extracellular mechanisms of secretin respectively, are proposed in Figure 4.1 and 
4.2. As illustrated in Figure 4.1, secretin modulates the GABAergic afferent activity 
through two distinguished parallel pathways: one is through the direct activation of 
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Figure 4.1 Schematic diagram illustrating the proposed model for the intracellular 
pathways of the action of secretin. 
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Figure 4.2 Schematic diagram illustrating the proposed model for the release and 
function of secretin in the cerebellar cortex. PC Purkinje cell; B C basket cell; CF 
climbing fiber; + inhibitory G A B A release input; - excitatory input 
second messenger system pathway with the involvement of P K A signal transduction 
cascade. O n the other hand, under the stimulation of secretin, glutamate is released 
from somewhere in the cerebellar cortex, acts on A M P A receptors on the presynaptic 
terminals, and then provides a complementary facilitation of G A B A release. W e are 
not sure on the intracellular mechanism of A M P A receptors yet. However, it is 
assumed that activation of these receptors may result in calcium influx through these 
channels and then modulation of the vesicular G A B A release, since A M P A type 
iGluRs are well known to be permeable to Ca^ "" (Bureau and Mulle, 1998). Figure 4.2 
demonstrates our proposal on the release and function of secretin in the cerebellar 
cortex. As we propose, secretin is released from Purkinje cells in the somatodendritic 
region when these Purkinje cells are depolarized, and acts on the secretin receptors on 
the presynaptic terminals from basket cells. This is consistent with the morphological 
presence of secretin in Purkinje cells, especially in the soma and the dendrites. Since 
Purkinje cells only receive two excitatory inputs, mossy fibers and climbing fibers. 
W e propose in Figure 4.2 that the depolarization could be caused by the excitatory 
terminals coming from climbing fibers. At the same time, there is glutamate release 
induced by secretin from somewhere in the cerebellar cortex, and acts on the A M P A 
receptors on presynaptic terminals. The resource of these glutamate is still not certain. 
In this model, we assume that glutamate may be co-released with secretin from 
Purkinje cells themselves also in the somatodendritic region. This may explain the 
morphological presence of secretin receptor in Purkinje cells, even though our 
pharmacological experiments have not proved any postsynaptic component of the 
action of secretin. Of course, it is also possible that the glutamate is released from 
other neurons in the cerebellar cortex. 
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4.3 Physiological role of secretin in the cerebellum 
What is the physiological role of secretin in the cerebellum? Our findings are 
consistent with the scenario that upon depolarization, Purkinje cells release secretin to 
stabilize themselves by facilitating the inhibitory inputs from the interneurons, very 
probably basket cells. The presence of secretin immunoreactivity in the soma and 
dendrites of Purkinje cells suggests that secretin is released in the somatodendritic 
region. Analogous somatodendritic release has been postulated for other peptide 
(Huang and Neher, 1996) and amino acid transmitters, such as G A B A and glutamate 
(Zilberter et al., 1999; Glitsch et al., 1996). In this context, secretin serves as a 
retrograde messenger and produces effects which are opposite to those of glutamate, 
another retrograde messenger postulated in the interneuron-Purkinj e cell synapse 
(Glitsch et al., 1996). Furthermore, the cerebellum is enriched with a set of distinct 
plastic phenomena including long-term depression, depolarization-induced inhibition 
and depolarization-induced rebound facilitation (Marty and Llano, 1995). The 
relatively long-lasting (> 30 min) effect of secretin in potentiating the IPSCs may 
underlie, or contribute to, depolarization-induced rebound facilitation which has been 
implied in the regulation of Purkinje cell excitability by climbing fibres and thus the 
motor learning function of the cerebellum (Kano et al., 1992). 
4.4 Secretin and autism 
It has been suggested that autism is a genetic disorder (Philippe et al., 1999). Current 
research links autism to biological or neurological differences in the brain, for 
instance, abnormalities in the structure of the brain (see Chapter 1.4). In fact, 
abnormalities of the cerebellum, such as the size and number of Purkinje cells, have 
long been suspected in the etiology of autism (Courchesne, 1997; Riva and Giorgi, 
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2000). More recently, the involvement of Purkinje cells in this disease is supported by 
a rat model of autism in which the cerebellar Purkinje cells of the virally infected 
brain are selectively destroyed (Pletnikov et al., 1999). Our results therefore provide a 
link for the speculative relationship between secretin, cerebellum and autism as well 
as an explanation for the potential use of secretin as a drug to treat this disease 
(Horvath et al., 1998). Nevertheless, in view of our observation that secretin and its 
receptor are also expressed in other brain regions (see Chapter 1.2 and 1.3), it is 
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